Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

March 14, 2024

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

June 09, 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

May 31, 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

May 22, 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

Good Long-term Results With FANTOM BVS, but More Data Needed

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

News Conference News TCT 2021

EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

Michael O'Riordan

October 15, 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.